The term nanocell refers to a drug delivery platform consisting of a polymer-bound chemotherapeutic drug combined with a lipid-bound anti-angiogenesis drug. Angiogenesis, or the formation of new blood vessels, plays a major role in the development of a tumor. For tumor cells cut off from the blood supply can eventually develop “reactive resistance” to hypoxia. These resistant cancer cells could be killed by chemotherapeutic drugs, but once the vasculature to the tumor has been cut off, there is no way for chemotherapy to be delivered. Nanochip offers a way to deliver chemotherapeutic drugs and anti-angiogenic drugs in the same vehicle so that as the blood supply is shut off, chemotherapy is present to prevent any hypoxia-resistant cells from proliferating.
Related Journals of Nanocell
International Journal of Nanomedicine, Nanomedicine: Nanotechnology, Biology and Medicine, Journal of Nanomedicine Research, European Journal of Nanomedicine